XBiotech Inc., a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XBIT
Previous Symbol
CUSIPN/A
Phone512-386-2900
Debt
Debt-to-Equity RatioN/A
Current Ratio9.26
Quick Ratio9.26
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.31 per share
Price / Book3.15
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-33,150,000.00
Net MarginsN/A
Return on Equity-41.44%
Return on Assets-39.54%
Miscellaneous
Employees51
Outstanding Shares35,820,000
Market Cap$147.94 million
OptionableOptionable
XBiotech (NASDAQ:XBIT) Frequently Asked Questions
What is XBiotech's stock symbol?
XBiotech trades on the NASDAQ under the ticker symbol "XBIT."
When is XBiotech's next earnings date?
Has XBiotech been receiving favorable news coverage?
News coverage about XBIT stock has trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. XBiotech earned a news sentiment score of 1.7 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the next several days.
Who are some of XBiotech's key competitors?
Some companies that are related to XBiotech include Collegium Pharmaceutical (COLL), CymaBay Therapeutics (CBAY), Rocket Pharmaceuticals (RCKT), Ra Pharmaceuticals (RARX), Basilea Pharmaceutica (BPMUF), Arvinas (ARVN), Insys Therapeutics (INSY), Eidos Therapeutics (EIDX), Arcus Biosciences (RCUS), GlycoMimetics (GLYC), ChemoCentryx (CCXI), Innate Pharma (IPHYF), Clementia Pharmaceuticals (CMTA), Kezar Life Sciences (KZR) and Beyondspring (BYSI).
Who are XBiotech's key executives?
XBiotech's management team includes the folowing people:
- Mr. John Simard, Founder, Pres, CEO & Chairman (Age 56)
- Dr. Sushma Shivaswamy, Chief Scientific Officer (Age 40)
- Ms. Queena Han B.A., CPA, C.G.A., VP of Fin. & HR and Sec. (Age 51)
- Mr. Benjamín Guzmán, Sr. VP of Corp. Strategy & Fin. (Age 62)
- Ms. Norma I. Gonzalez, VP of Quality (Age 61)
When did XBiotech IPO?
(XBIT) raised $76 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $18.00-$20.00 per share. WR Hambrecht + Co acted as the underwriter for the IPO.
How do I buy shares of XBiotech?
Shares of XBIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is XBiotech's stock price today?
One share of XBIT stock can currently be purchased for approximately $4.13.
How big of a company is XBiotech?
XBiotech has a market capitalization of $147.94 million. XBiotech employs 51 workers across the globe.
What is XBiotech's official website?
How can I contact XBiotech?
XBiotech's mailing address is 5217 WINNEBAGO LN, AUSTIN TX, 78744. The biopharmaceutical company can be reached via phone at 512-386-2900 or via email at [email protected]
MarketBeat Community Rating for XBiotech (NASDAQ XBIT)
MarketBeat's community ratings are surveys of what our community members think about XBiotech and other stocks. Vote "Outperform" if you believe XBIT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XBIT will underperform the S&P 500 over the long term. You may vote once every thirty days.
